PDF herunterladen
Semin Thromb Hemost 2003; 29(6): 639-644
DOI: 10.1055/s-2004-815631
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Anticardiolipin β2-Glycoprotein I Antibody: Is a High Titer Related to Unfavorable Pregnancy Outcome?

Hideto Yamada1,2 , Emi H. Kato2 , Mamoru Morikawa2 , Shigeki Shimada2 , Yasuhiko Ebina2 , Noriaki Sakuragi2 , Shigenori Suzuki2 , Hisanori Minakami2
  • 1Associate Professor, Department of Obstetrics and Gynecology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
  • 2Department of Obstetrics and Gynecology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
13. Januar 2004 (online)

    Lizenzen und Reprints

ABSTRACT

We present the clinical characteristics of pregnancy histories and subsequent pregnancy outcomes of 13 women who tested positive for anticardiolipin β2-glycoprotein I antibody (aCLβ2GPI). Six of the 13 women had a history of recurrent spontaneous abortion (RSA). The prevalence of aCLβ2GPI syndrome among women with RSA was very low (2.1%). Other women with aCLβ2GPI were identified by the presence of a biological false-positive serological test for syphilis, intrauterine growth restriction (IUGR), and a history of thrombosis. However, serum aCLβ2GPI titers in the 13 women varied, with a wide range from 3.6 to 1468 U/mL. Their pregnancy histories, subsequent pregnancy outcomes, and complications were compared according to the classification of serum aCLβ2GPI titers as low, moderate, or high. The history of second trimester fetal death was found only in women with high serum aCLβ2GPI titers. All women with high serum aCLβ2GPI titers experienced severe maternal-fetal complications such as IUGR, fetal distress, systemic thromboembolism, and neonatal sequelae in subsequent pregnancies.

KEYWORDS

Anticardiolipin β2-glycoprotein I antibody - antiphospholipid antibody syndrome - intrauterine fetal death - recurrent spontaneous abortion

REFERENCES

  • 1 Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease.  Lancet . 1990;  336 177-178
    PubMedGoogle Scholar
  • 2 McNeil H P, Simpson R J, Chesterman C N, Krilis S A. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H).  Proc Natl Acad Sci U S A . 1990;  87 4120-4124
    CrossrefPubMedGoogle Scholar
  • 3 Galli M, Comfurius P, Maassen C. et al . Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma cofactor.  Lancet . 1990;  335 1544-1547
    CrossrefPubMedGoogle Scholar
  • 4 Koike T, Matsuura E. What is the “true” antigen for anticardiolipin antibodies?.  Lancet . 1991;  337 671-672
    PubMedGoogle Scholar
  • 5 Matsuura E, Igarashi Y, Fujimoto M. et al . Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor.  J Immunol . 1992;  148 3885-3891
    PubMedGoogle Scholar
  • 6 Ozawa N, Makino T, Matsubayashi H. et al . β2-GPI-dependent and independent binding of anticardiolipin antibodies in patients with recurrent spontaneous abortions.  J Clin Lab Anal . 1994;  8 255-259
    PubMedGoogle Scholar
  • 7 Aoki K, Dudkiewicz A B, Matsuura E, Novotny M, Kaberlein G, Gleicher N. Clinical significance of β2-glycoprotein I-dependent anticardiolipin antibodies in the reproductive autoimmune failure syndrome: correlation with conventional antiphospholipid antibody detection systems.  Am J Obstet Gynecol . 1995;  172 926-931
    CrossrefPubMedGoogle Scholar
  • 8 Katano K, Aoki A, Sasa H, Ogasawara M, Matsuura E, Yagami Y. Beta 2-Glycoprotein I-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women.  Hum Reprod . 1996;  11 509-512
    PubMedGoogle Scholar
  • 9 Gleicher N, el-Roeiy A, Confino E, Friberg J. Is endometriosis an autoimmune disease?.  Obstet Gynecol . 1987;  70 115-122
    PubMedGoogle Scholar
  • 10 Higashino M, Takakuwa K, Arakawa M, Tamura M, Yasuda M, Tanaka K. Anti-cardiolipin antibody and anti-cardiolipin beta-2-glycoprotein I antibody in patients with recurrent fetal miscarriage.  J Perinat Med . 1998;  26 384-389
    CrossrefPubMedGoogle Scholar
  • 11 Ogasawara M, Aoki K, Katano K, Aoyama T, Kajiura S, Suzumori K. Prevalence of autoantibodies in patients with recurrent miscarriages.  Am J Reprod Immunol . 1999;  41 86-90
    PubMedGoogle Scholar
  • 12 Silveira L H, Hubble C L, Jara L J. et al . Prevention of anticardiolipin antibody-related pregnancy losses with prednisone and aspirin.  Am J Med . 1992;  93 403-411
    CrossrefPubMedGoogle Scholar
  • 13 Silver R K, MacGregor S N, Sholl J S, Hobart J M, Neerhof M G, Ragin A. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients.  Am J Obstet Gynecol . 1993;  169 1411-1417
    PubMedGoogle Scholar
  • 14 Laskin C A, Bombardier C, Hannah M E. et al . Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss.  N Engl J Med . 1997;  337 148-153
    CrossrefPubMedGoogle Scholar
  • 15 Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies).  BMJ . 1997;  314 253-257
    CrossrefPubMedGoogle Scholar
  • 16 Kutteh W H. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone.  Am J Obstet Gynecol . 1996;  174 1584-1589
    CrossrefPubMedGoogle Scholar
  • 17 Wilson W A, Gharavi A E, Koike T. et al . International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.  Arthritis Rheum . 1999;  42 1309-1311
    CrossrefPubMedGoogle Scholar
      >